Advaxis to Host Investor & Analyst Day on June 12
May 18 2017 - 8:00AM
Business Wire
Focus on Patients, Partnerships and
Progress
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, today announced that it will
host its annual Investor & Analyst Day on Monday, June 12, at
1:00 p.m. in New York, NY. The event will feature presentations
followed immediately by a reception.
Event:
Advaxis Investor & Analyst Day
Date:
Monday, June 12, 2017
Time:
1:00 – 4:00 p.m. ET, Reception from 4:00 –
5:00 p.m.
Location:
Offices of Reed Smith 599 Lexington Avenue, 22nd Floor New York, NY
10022
At this year’s Investor & Analyst Day, Advaxis will focus on
“Patients, Partnerships and Progress” with presentations centering
around the following areas:
- Clinical Trial Update with Case Study
Highlights
- Plans for Data Dissemination and
Timelines
- Update on Advaxis’ Corporate
Collaborations
- Research Update on the NEO and HOT
Programs
- Progress Towards Regulatory Submission
and Commercial Readiness
During the Investor & Analyst Day, several investigators
involved in Advaxis’ ongoing clinical trials will highlight their
experiences and case studies in an interactive clinical symposium.
An update will be provided on the company’s global Phase 3 AIM2CERV
study, as well as a planned potentially registrational quality
study of axalimogene filolisbac for the treatment of metastatic
cervical cancer. In addition, the team will review the plans to
file for marketing authorization for axalimogene filolisbac in the
European Union this year, an update on the clinical collaboration
with Amgen, Inc. on ADXS-NEO and more.
Attendance and Participation
To register for the event, please visit: www.advaxis.com.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology™. Lm Technology,
using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer
immunotherapy agent shown in preclinical studies to both generate
cancer fighting T cells directed against cancer antigens and
neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that
protect the tumor microenvironment from immunologic attack and
contribute to tumor growth. Advaxis' lead Lm Technology
immunotherapy, axalimogene filolisbac, targets HPV-associated
cancers and currently has multiple clinical trials underway,
including Phase 3 in invasive cervical cancer, Phase 2 in head and
neck cancer, and Phase 2 in anal cancer. The FDA has granted
axalimogene filolisbac orphan drug designation for each of these
three clinical settings, as well as Fast Track designation for
adjuvant therapy for high-risk, locally advanced cervical cancer
(HRLACC) patients and a SPA for the Phase 3 AIM2CERV trial in
HRLACC patients. Axalimogene filolisbac has also been classified as
an advanced therapy medicinal product for the treatment of cervical
cancer by the European Medicines Agency’s Committee for Advanced
Therapies. Advaxis has two additional immunotherapy products:
ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid
tumors, in human clinical development. In addition, Advaxis and
Amgen are developing ADXS-NEO, an investigational cancer
immunotherapy treatment designed to activate a patient's immune
system to respond against the unique mutations, or neoepitopes,
contained in and identified from each individual patient's tumor,
with plans to enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary immunotherapy,
axalimogene filolisbac. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170518005590/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia Contact:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024